Weifang Ruze New Material Co., Ltd.

 

Your Aspiration is Our Commitment

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsAntineoplastic Drugs

Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7

Ruze supply good service, thanks.

—— Gaurav

I'm Online Chat Now

Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7

China Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7 supplier
Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7 supplier Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7 supplier

Large Image :  Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7

Product Details:

Place of Origin: Weifang,China
Brand Name: RuzE
Model Number: TC-6003

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Packaging Details: 1kg, 25kg or As customer request
Delivery Time: 5-10work days
Payment Terms: L/C, T/T, Western Union, MoneyGram
Supply Ability: 50kg/Month
Contact Now
Detailed Product Description
Product Name: Regorafenib Synonyms: Regorafenib - BAY 73-4506 | Stivarga;Regorafenib(W.S)
CAS: 755037-03-7 MF: C21H15ClF4N4O3
MW: 482.8154128 EINECS: 815-051-1
Mol File: 755037-03-7.mol

Weifang Ruze New Material Co.,LTD a China supplier of Regorafenib (CAS No.: 755037-03-7),CAS 755037-03-7 offers for your requirements of RND, evaluation, pilots and commercial along with supportive technical package required for evaluation.

 

Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7

 

Regorafenib CAS:755037-03-7

 

[PRODUCT NAME]:Regorafenib

[CATALOG NUMBER]:

[STRUCTURE]:

[CAS NUMBER]:755037-03-7

[MOLECULAR FORMULA]:C21H15ClF4N4O3

[MOLECULAR WEIGHT]:482.81500

[BATCH NO]:20190224

[TEST]:SPECIFICATION

[APPEARANCE]:Off-white Crystal Powder

[ASSAY]: 99%min

[WATER]:0.5%max


Regorafenib Chemical Properties


Melting point 206.0 to 210.0 °C
form White powder.
CAS DataBase Reference 755037-03-7

Safety Information


HS Code 29242990

MSDS Information


Regorafenib Usage And Synthesis


Description In September 2012, theUSFDAapproved regorafenib for the treatment of patients with metastatic colorectal cancer (CRC), especially those for whom standard therapies have failed, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, ananti-EGFRtherapy. Regorafenib is a multikinase inhibitor with potent inhibitory activity versus VEGFRs and PDFRs. Both of these classes of receptors are expressed on tumor cells and affect proliferation and angiogenesis. Regorafenib inhibited growth in murine xenograft models for colon, breast, renal, lung, melanoma, pancreatic, and ovarian tumors when dosed at 10–30 mg/kg. Regorafenib is a fluorinated analog of sorafenib, a multikinase inhibitor co-marketed by Bayer and Onyx for the treatment of kidney and liver cancer. The synthesis of regorafenib is accomplished in two steps from commercially available starting materials. 4-Aminophenol is coupled to 4-chloro-N-methyl- 2-pyridinecarboxamide to give 4-(2-(N-methylcarbamoyl)-4-pyridyloxy)aniline. Subsequent treatment with 4-chloro-3-(trifluoromethyl)phenyl isocycanate affords the urea, regorafenib.
Originator Bayer (Germany)
Uses It inhibits PDGFR tyrosine kinase with IC50=83nM. It is useful for the treatment of inflammation and as an anti-proliferative agent.
Uses BAY 73-4506 (Regorafenib) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf.
Uses Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively
Definition ChEBI: A pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previ usly received chemotherapy, anti-EGFR or anti-VEGF therapy.
Brand name Stivarga

 

 

Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7

Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7

 

Anti-cancer metastatic colorectal cancer (CRC) Regorafenib CAS:755037-03-7

Weifang Ruze New Material Co.,LTD supply free sample and datebase on Regorafenib (CAS No.: 755037-03-7), if you want futher information about Regorafenib (CAS No.: 755037-03-7), please feel free to contract us.

Contact Details
Weifang Ruze New Material Co., Ltd.

Contact Person: Ruze02

Send your inquiry directly to us (0 / 3000)